Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor

Li, Jian; Ye, Yingjiang; Wang, Jian; Zhang, Bo; Qin, Shukui; Shi, Yingqiang; He, Yulong; Liang, Xiaofeng; Liu, Xiufeng; Zhou, Ye; Wu, Xin; Zhang, Xinhua; Wang, Ming; Gao, Zhidong; Lin, Tianlong; Cao, Hui; Shen, Lin; GIST, CSCO Expert Committee on

doi:10.21147/j.issn.1000-9604.2017.04.01

Cited by 128 publications

(138 citation statements)

References 58 publications

Supporting

Mentioning

137

Contrasting

Order By: Relevance

“…It is unclear whether these guidelines are appropriate for the clinical situation in Asian countries, especially China, given the long-lasting experience of selected Chinese centers [13]. The Chinese consensus guidelines for the diagnosis and management of GISTs were formulated in 2013 and updated in 2017, and differ from those of European countries in terms of clinical practice patterns [5]. In this review, we will summarize the clinical practice of both China and European countries and then discuss the similarities and differences between the European and Chinese GIST guidelines, although the fundamental approaches to the diagnostic and treatment strategy for GISTs are very similar.…”

Section: Clinical Management Guidelinesmentioning

confidence: 99%

“…IHC staining of GIST is recommended using a panel with five markers including CD117, DOG1, CD34, succinate dehydrogenase B (SDHB), and Ki67. SDHA markers could be added as appropriate [5,15,16]. …”

Section: Pathological Diagnosis and Genetic Analysismentioning

confidence: 99%

“…A systematic review of population-based cohort studies on GISTs showed that the incidence ranges from a low 0.43 per 100,000/year in the Shanxi Province, China, to a high 1.6-2.2 per 100,000/year in South Korea [4,5,6]. The cohort of 13,550 patients from 19 countries studied in this review gave the reported age as ranging from 10-100 years, with a median age in the 60s; both male and female populations had approximately equal distribution [7].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe

Tu¹,

Hohenberger²,

Allgayer³

et al. 2018

Visc Med

Self Cite

View full text Add to dashboard Cite

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. With the considerable research and application of molecular-targeted therapy for GISTs in the last two decades, GISTs have become a model of multidisciplinary oncological treatment. Although Western clinical guidelines are available for GISTs, such as those by the European Society of Medical Oncology (ESMO), the clinical situations in China are different from those in European countries. There are distinct differences between the clinical practice, diagnostic methods, surgical approach, and availability of new targeted agents in China and those in Europe. This review summarizes the Chinese GIST consensus guidelines compared to the European ones, which may provide an optimal approach to the diagnosis and management of GIST patients.

show abstract

Section: Clinical Management Guidelinesmentioning

confidence: 99%

Section: Pathological Diagnosis and Genetic Analysismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe

Tu¹,

Hohenberger²,

Allgayer³

et al. 2018

Visc Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…In clinical practice, Chinese physicians refer to the Chinese consensus of GISTs, National Comprehensive Cancer Network (NCCN) guidelines, and European Society for Medical Oncology (ESMO) guidelines for clinical diagnosis and treatment . To our knowledge to date, 4 Chinese consensus versions have been updated, and the latest edition was published in 2017 in English . The Chinese consensus is based mainly on high‐level medical evidence worldwide and the research data for Chinese patients.…”

Section: Introductionmentioning

confidence: 99%

“…However, unlike patients with high‐risk GISTs, for whom adjuvant therapy is recommended for 3 years, to our knowledge the duration of adjuvant therapy for patients with intermediate‐risk GISTs is not clearly specified; the ESMO guidelines recommend that a shared decision‐making process is needed when the risk is intermediate . Based on 2 Chinese studies, the Chinese consensus recommended that patients with GISTs located in the small intestine or rectum that are of intermediate risk should receive adjuvant therapy for 3years, whereas patients with gastric GISTs that are of intermediate risk only require adjuvant therapy for 1 year …”

Section: Introductionmentioning

confidence: 99%

The current status of and prospects in research regarding gastrointestinal stromal tumors in China

Shen

2020

Cancer

Self Cite

View full text Add to dashboard Cite

China still lacks statistical data regarding the incidence of gastrointestinal stromal tumors (GISTs). Data from 3 regions have demonstrated that the incidence of GISTs in China is similar to that in the United States. Furthermore, no significant differences between both nations with regard to epidemiological characteristics and genotyping of GISTs have been reported. Chinese physicians are demonstrating an increased interest in studies regarding GISTs. Currently, to the authors' knowledge, China publishes the most research articles regarding GIST annually worldwide. Despite the paucity of relevant research regarding the clinical practices for GISTs, a series of studies performed by Chinese physicians in the fields of recurrence risk classification, laparoscopic surgery, and adjuvant therapy have contributed to the diagnosis and treatment of GISTs. The lack of innovative drugs, slow approval of new drugs, and insufficient research funds have limited further advancements in GIST‐related research in China. In recent years, increased investment in scientific research has allowed for these advancements to be made by creating conditions for Chinese physicians to conduct high‐level clinical research. Chinese researchers hope to further shorten the gap between China and the rest of the world in the field of GIST research within a relatively short period. The purpose of the current review article was to present the most updated information regarding the diagnosis and treatment of GISTs in Chinese medical practice and to suggest prospective research in this field.

show abstract

Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors

Shen

Wang

et al. 2020

Cancer Medicine

Self Cite

View full text Add to dashboard Cite

Background Gastrointestinal stromal tumors (GISTs) with different types of mutations exhibit different clinical characteristics and prognosis. This study aimed to evaluate the prognostic value of mutations in KIT and PDGFRA in a large‐scale cohort of GIST patients with current therapy including surgery and imatinib. Methods A total of 1163 patients diagnosed with GISTs between January 2006 and December 2018 were enrolled in this study. Mutation analysis was performed for exons 9, 11, 13, and 17 of KIT and exons 12 and 18 of PDGFRA. Mutations were grouped into 12 categories according to the gene, exon, and involved codons; they were analyzed considering the clinical characteristics, disease‐free survival (DFS), and overall survival (OS) of patients with GISTs. Results In low‐risk GISTs, we identified two predictors of worse DFS: tumor origin in the rectum and KIT exon 11 deletion involving two or more codons. In high‐risk GISTs treated with R0 resection and imatinib, patients with KIT exon 11 homozygous mutations and KIT intron 10/exon 11 junction deletions demonstrated the highest recurrence rate, indicating that these mutations can be independent prognostic factors of DFS. The presence of KIT exon 11 homozygous mutations also independently influenced OS. Conclusion Low‐incidence mutations such as KIT exon 11 homozygous mutations or intron 10/exon 11 junction deletions in GISTs should be carefully evaluated to explore novel treatment strategies, as tumors with these mutations have a high recurrence rate and a very poor prognosis after surgery followed by imatinib adjuvant treatment.

show abstract

Chinese consensus guidelines for diagnosis and management of gastrointestinal stromal tumor

Cited by 128 publications

References 58 publications

Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe

Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe

The current status of and prospects in research regarding gastrointestinal stromal tumors in China

Exon 11 homozygous mutations and intron 10/exon 11 junction deletions in the KIT gene are associated with poor prognosis of patients with gastrointestinal stromal tumors

Contact Info

Product

Resources

About